ERBB2 and adenocarcinoma: A phase II study recently investigated a novel EGFR/HER2 inhibitor, pyrotinib, in heavily pre-treated patients with HER2-mutant adenocarcinomas and found a promising results with RR of 54.5%(6/11) and median PFS of 6.2 months [9].